

Licensed products in pre-clinical & clinical phases

Reference	Indication/ Use	R+D	Pre-clinical	Phase I	Phase II	Phase III	Licensed	Research group
EYE-SCAFF project	LSCD syndrome						ferrer	CB06/01/0003
Procedure for the procurement of solid micro- or nanoparticles	Administration of medicines						nanomol Technologies	CB06/01/0033
Targeted delivery of therapeutic molecules to CXCR4 cells	Colorectal cancer						NANOLIGENT	CB06/01/0014 CB06/01/1031
Nanostructured proteins	Cancer						NANOLIGENT	CB06/01/0014 CB06/01/1031
Therapeutic nanoconjugates (1)	Cancer					To download	NANOLIGENT	CB06/01/0014 CB06/01/1031
Therapeutic nanoconjugates (2)	Cancer						NANOLIGENT	CB06/01/0014 CB06/01/1031
Scaffold Proteins and Therapeutic Nanoconjugates	Cancer						NANOLIGENT	CB06/01/0014 CB06/01/1031